Concerns about important biases, such as selection bias, serious confounding by indication, detection bias, or reverse causality, limit the interpretation of some previous observational studies quantifying dementia risk associated with GLP1 receptor agonists (Supplementary Table 14 for further details)
However, safe and effective use requires understanding appropriate formulations, dosing, and when to seek medical advice
Dosing and schedule All GLP-1s used for weight loss follow a step-up dosing schedule
(NAD+ in aging, metabolism, and neurodegeneration)
For a common approved-medicine comparison, Mounjaro vs Ozempic may help frame tirzepatide and semaglutide differences